A Texas federal court denied a compounding pharmacy trade association's motion to freeze the FDA's decision to end the shortage of semaglutide (marketed as Ozempic and Wegovy). The group unsuccessfully argued that there is still a shortage of the drug.

Why it matters: The hits keep coming to companies that have been selling cheaper, copycat versions of brand-name GLP-1 weight loss drugs that were in short supply.

You've read 0 of 2 free articles this month.

Get more articles - create your free account today!

Products

Events & Resources

Topics

Latest Articles

Shoppers hate paying for return shipping more than any other part of the process

Doctors expect longer visits as parents seek clarity about pediatric vaccine guidelines

Lowe’s reaches out to Gen Alpha with new rewards program for kids

Meta faces critical questions as AI spending and regulatory scrutiny intensify

J&J launches direct-to-consumer prescription drug site with lower cash prices

The health and fitness industry’s future is subscription-first, not hardware-led

Scam exposure on social platforms threatens brands

Email is consumers’ top marketing channel, but inbox fatigue threatens ROI

How payment providers should react to OpenAI’s Instant Checkout walkback

Capital One joins finance industry layoff trend, sheds 1,100 Discover workers

About

Novo Nordisk gets a win in court against pharmacies that make compounded GLP-1s

Coverage Areas →

Coverage Areas →

Advertising & Marketing

Health

Ecommerce & Retail

Technology

Financial Services

More Topics

Geographies

EMARKETER

Media Services

Free Content

Contact Us →

Worldwide HQ

Sales Inquiries